Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen

Human Pathology

Volumn 40, Issue 3, 2009, Pages 405-412

  Kelley, Todd W ^a   Baz, Rachid ^b   Hussein, Mohamad ^c   Karafa, Matthew ^a   Cook, James R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c CELGENE CORPORATION   (United States)

Author keywords

Cyclin D1; Cyclin D3; FGFR3; Immunohistochemistry; Myeloma; p53; Thalidomide

Indexed keywords

CYCLIN D1; DEXAMETHASONE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PREDNISONE; PROTEIN P53; THALIDOMIDE; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COURSE EVALUATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA RELAPSE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL NUCLEUS; CLINICAL TRIALS, PHASE II AS TOPIC; CYCLIN D1; DEXAMETHASONE; DOXORUBICIN; FEMALE; FIBROBLAST GROWTH FACTOR 3; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OHIO; POLYETHYLENE GLYCOLS; SURVIVAL RATE; THALIDOMIDE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE;

EID: 59049084019     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.09.006     Document Type: Article

References (34)

1. Zhan F., Huang Y., Colla S., et al. The molecular classification of multiple myeloma. Blood 108 (2006) 2020-2028
2. Hideshima T., Bergsagel P.L., Kuehl W.M., et al. Advances in biology of multiple myeloma: clinical applications. Blood 104 (2004) 607-618
3. Stewart A.K., and Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 23 (2005) 6339-6344
4. Fonseca R., Barlogie B., Bataille R., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64 (2004) 1546-1558
5. Bergsagel P.L., Kuehl W.M., Zhan F., et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106 (2005) 296-303
6. Barille-Nion S., Barlogie B., Bataille R., et al. Advances in biology and therapy of multiple myeloma. Hematology Am Soc Hematol Educ Program (2003) 248-278
7. Bergsagel P.L., and Kuehl W.M. Chromosome translocations in multiple myeloma. Oncogene 20 (2001) 5611-5622
8. Bergsagel P.L., and Kuehl W.M. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 194 (2003) 96-104
9. Bergsagel P.L., and Kuehl W.M. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23 (2005) 6333-6338
10. Chang H., Qi C., Yi Q.L., et al. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105 (2005) 358-360
11. Fonseca R., Debes-Marun C.S., Picken E.B., et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102 (2003) 2562-2567
12. Drach J., Ackermann J., Fritz E., et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92 (1998) 802-809
13. Cook J.R., Hsi E.D., Worley S., et al. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival. Am J Clin Pathol 125 (2006) 615-624
14. Chang H., Yeung J., Qi C., et al. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma. Br J Haematol 138 (2007) 324-329
15. Pruneri G., Carboni N., Baldini L., et al. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation. Hum Pathol 34 (2003) 41-47
16. Chang H., Stewart A.K., Qi X.Y., et al. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 106 (2005) 353-355
17. Hussein M.A., Baz R., Srkalovic G., et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 81 (2006) 889-895
18. Larson A., and Cook J.R. Fibroblast growth factor receptor 3 (FGFR3) expression in malignant lymphomas. Appl Immunohistochem Mol Morphol 16 (2008) 322-325
19. Cook J.R., Hartke M., Pettay J., et al. Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence. J Mol Diagn 8 (2006) 459-465
20. Soverini S., Cavo M., Cellini C., et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 102 (2003) 1588-1594
21. Troussard X., Avet-Loiseau H., Macro M., et al. Cyclin D1 expression in patients with multiple myeloma. Hematol J 1 (2000) 181-185
22. Avet-Loiseau H., Facon T., Grosbois B., et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99 (2002) 2185-2191
23. Specht K., Haralambieva E., Bink K., et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 104 (2004) 1120-1126
24. Pruneri G., Fabris S., Baldini L., et al. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol 156 (2000) 1505-1513
25. Hoechtlen-Vollmar W., Menzel G., Bartl R., et al. Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance. Br J Haematol 109 (2000) 30-38
26. Kuehl W.M., and Bergsagel P.L. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology Am Soc Hematol Educ Program (2005) 346-352
27. Fonseca R., Blood E., Rue M., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101 (2003) 4569-4575
28. Chesi M., Nardini E., Brents L.A., et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16 (1997) 260-264
29. Chang H., Sloan S., Li D., et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 125 (2004) 64-68
30. Gutierrez N.C., Castellanos M.V., Martin M.L., et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 21 (2007) 143-150
31. Ho P.J., Brown R.D., Spencer A., et al. Thalidomide post-autologous stem cell transplant (ASCT) improves progress-free survival (PFS) in myeloma with normal but not up-regulated FGFR3 expression and may overcome the poor prognostic effect of t(4;14). Heaematologica 92 S2 (2007) 194 [ABSTRACT]
32. Kumar S., and Rajkumar S.V. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 42 (2006) 1612-1622
33. Cavallo F., Boccadoro M., and Palumbo A. Review of thalidomide in the treatment of newly diagnosed multiple myeloma. Ther Clin Risk Manag 3 (2007) 543-552
34. Bahlis N.J., Song K., Trieu Y., et al. Lenalidomide overcomes poor prognosis conferred by del13q and t(4;14) but not del17p13 in multiple myeloma: results of the Canadian MM016 trial. Blood 110 (2007) 1052A [ABSTRACT]